Apnimed, Inc. (APMD)
NasdaqGS · Biotechnology
Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.
Price history
Daily closes and volumeAI Analysis Generated from the indicator readings below. Educational only.
Apnimed, Inc. is trading at $16.40, down 5.42% on the session. The 50 day average sits at $22.93 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 35.3, which reads as weak, and MACD is bullish crossover. Volume is above average.
The nearest support is around $16.16 with resistance near $19.57, so that band frames the current range. Average daily movement is roughly $1.82, or about 11.1% of the share price, which is what any stop placement has to allow for. The overall health score of 31 out of 100 combines a trend score of 25, momentum of 44 and a risk score of 22.
Technical indicators
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Company website